Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Trimethylamine-N-Oxide (TMAO) predicts cardiovascular mortality in peripheral artery disease

  • Roncal Mancho, Carmen
  • Martínez Aguilar, Esther
  • Orbe, Josune
  • Ravassa, Susana
  • Fernández-Montero, Alejandro
  • Saenz-Pipaon, Goren
  • Ugarte, Ana
  • Estella-Hermoso de Mendoza, Ander
  • Rodríguez, José Antonio
  • Fernández Alonso, Sebastián
  • Fernández Alonso, Leopoldo
  • Oyarzabal, Julen
  • Páramo, José A.
Peripheral artery disease (PAD) is a major cause of acute and chronic illness, with extremely poor prognosis that remains underdiagnosed and undertreated. Trimethylamine-N-Oxide (TMAO), a gut derived metabolite, has been associated with atherosclerotic burden. We determined plasma levels of TMAO by mass spectrometry and evaluated their association with PAD severity and prognosis. 262 symptomatic PAD patients (mean age 70 years, 87% men) categorized in intermittent claudication (IC, n = 147) and critical limb ischemia (CLI, n = 115) were followed-up for a mean average of 4 years (min 1-max 102 months). TMAO levels were increased in CLI compared to IC (P < 0.001). Receiver operating characteristic (ROC) curves for severity (CLI) rendered a cutoff of 2.26 µmol/L for TMAO (62% sensitivity, 76% specificity). Patients with TMAO > 2.26 µmol/L exhibited higher risk of cardiovascular death (subhazard ratios ≥2, P < 0.05) that remained significant after adjustment for confounding factors. TMAO levels were associated to disease severity and CV-mortality in our cohort, suggesting an improvement of PAD prognosis with the measurement of TMAO. Overall, our results indicate that the intestinal bacterial function, together with the activity of key hepatic enzymes for TMA oxidation (FMO3) and renal function, should be considered when designing therapeutic strategies to control gut-derived metabolites in vascular patients., This work was supported by the Foundation for Applied Medical Research, Universidad de Navarra (Spain); European Fund for Economic and Regional Development (FEDER) funds [FIS PI18/01195], Ministry of Economy and Competitiveness, Institute of Health Carlos III, [CIBER-CV (CB16/11/00371)]. Patrimonio Praga (Mexico) and Virto Group (Spain).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Urinary extracellular vesicles for diabetic kidney disease diagnosis

  • Saenz-Pipaon, Goren
  • Echeverría Ilundáin, Saioa
  • Orbe, Josune
  • Roncal Mancho, Carmen
Diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD) in developed countries, affecting more than 40% of diabetes mellitus (DM) patients. DKD pathogenesis is multifactorial leading to a clinical presentation characterized by proteinuria, hypertension, and a gradual reduction in kidney function, accompanied by a high incidence of cardiovascular (CV) events and mortality. Unlike other diabetes-related complications, DKD prevalence has failed to decline over the past 30 years, becoming a growing socioeconomic burden. Treatments controlling glucose levels, albuminuria and blood pressure may slow down DKD evolution and reduce CV events, but are not able to completely halt its progression. Moreover, one in five patients with diabetes develop DKD in the absence of albuminuria, and in others nephropathy goes unrecognized at the time of diagnosis, urging to find novel noninvasive and more precise early diagnosis and prognosis biomarkers and therapeutic targets for these patient subgroups. Extracellular vesicles (EVs), especially urinary (u)EVs, have emerged as an alternative for this purpose, as changes in their numbers and composition have been reported in clinical conditions involving DM and renal diseases. In this review, we will summarize the current knowledge on the role of (u)EVs in DKD., This research was funded by “Instituto de Salud Carlos III-FEDER,” Fondo de Investigaciones Sanitarias [PI18/01195] and CIBERCV (CB16/11/00371). G.S.-P. was funded with a PhD scholarship from The Foundation for Applied Medical Research, Universidad de Navarra (Spain).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Reduced high-density lipoprotein cholesterol: a valuable, independent prognostic marker in peripheral arterial disease

  • Martínez Aguilar, Esther
  • Orbe, Josune
  • Fernández-Montero, Alejandro
  • Fernández Alonso, Sebastián
  • Rodríguez, José Antonio
  • Fernández Alonso, Leopoldo
  • Páramo, José A.
  • Roncal Mancho, Carmen
Objective The prognosis of patients with peripheral arterial disease (PAD) is characterized by an exceptionally high risk for myocardial infarction, ischemic stroke, and death; however, studies in search of new prognostic biomarkers in PAD are scarce. Even though low levels of high-density lipoprotein cholesterol (HDL-C) have been associated with higher risk of cardiovascular (CV) complications and death in different atherosclerotic diseases, recent epidemiologic studies have challenged its prognostic utility. The aim of this study was to test the predictive value of HDL-C as a risk factor for ischemic events or death in symptomatic PAD patients. Methods Clinical and demographic parameters of 254 symptomatic PAD patients were recorded. Amputation, ischemic coronary disease, cerebrovascular disease, and all-cause mortality were recorded during a mean follow-up of 2.7 years. Results Multivariate analyses showed that disease severity (critical limb ischemia) was significantly reduced in patients with normal HDL-C levels compared with the group with low HDL-C levels (multivariate analysis odds ratio, 0.09; 95% confidence interval [CI], 0.03-0.24). A decreased risk for mortality (hazard ratio, 0.46; 95% CI, 0.21-0.99) and major adverse CV events (hazard ratio, 0.38; 95% CI, 0.16-0.86) was also found in patients with normal vs reduced levels of HDL-C in both Cox proportional hazards models and Kaplan-Meier estimates, after adjustment for confounding factors. Conclusions Reduced HDL-C levels were significantly associated with higher risk for development of CV complications as well as with mortality in PAD patients. These findings highlight the usefulness of this simple test for early identification of PAD patients at high risk for development of major CV events., This work was supported by the Foundation for Applied Medical Research, University of Navarra (Pamplona, Spain); European Fund for Economic and Regional Development (FEDER) funds (FIS PI14/01152); and the Ministry of Economy and Competitiveness, Institute of Health Carlos III (RIC [RD12/ 0042/0009] and CIBER-CV [CB16/11/00371]).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Lipocalin-2 and calprotectin potential prognosis biomarkers in peripheral arterial disease

  • Saenz-Pipaon, Goren
  • Ravassa, Susana
  • Larsen, Katrine L.
  • Martínez Aguilar, Esther
  • Orbe, Josune
  • Rodríguez, José Antonio
  • Fernández Alonso, Leopoldo
  • González, Arantxa
  • Martín-Ventura, José Luis
  • Páramo, José A.
  • Lindholt, Jes S.
  • Roncal Mancho, Carmen
Objective: Peripheral arterial disease (PAD) is the most prevalent cardiovascular (CV) condition globally. Despite the high CV risk of PAD patients, no reliable predictors of adverse clinical evolution are yet available. In this regard, previous transcriptomic analyses revealed increased expression of calprotectin (S100A8/A9) and lipocalin-2 (LCN2) in circulating extracellular vesicles (EVs) of patients with PAD. The aim of this study was to determine the prognostic value of LCN2 and calprotectin for CV risk assessment in PAD. Methods: LCN2 and the S100A9 subunit of calprotectin were examined in human femoral plaques by immunohistochemistry and qPCR. LCN2 and calprotectin were determined by ELISA in PAD (CHN cohort, n ¼ 331, Fontaine IIeIV, serum), and PAD diagnosed by population based screening (VIVA trial, n ¼ 413, the majority Fontaine 0eI, plasma). Patients were followed up for a mean of four years, recording the primary outcomes; CV death or amputation in the CHN cohort and CV death or major lower limb events (MALE) in the VIVA population. Secondary outcomes were all cause death or amputation, and all cause death or MALE, respectively. Results: LCN2 and S100A9 were detected in human plaques in regions rich in inflammatory cells. LCN2 and calprotectin levels were 70% and 64% lower in plasma than in serum. In the CHN cohort, high serum levels of LCN2 and calprotectin increased the risk of primary and secondary outcomes 5.6 fold (p < .001) and 1.8 fold (p ¼ .034), respectively, after covariable adjustment. Similarly, elevated plasma levels of LCN2 and calprotectin increased by three fold the risk of primary and secondary outcomes (p < .001) in the VIVA cohort. Moreover, addition of the combined variable to basal models, considering clinically relevant risk factors, improved reclassification for the primary outcome in both cohorts (p .024). Conclusion: Combined assessment of the inflammatory biomarkers LCN2 and calprotectin might be useful for risk stratification in advanced and early PAD., The Foundation for Applied Medical Research, Universidad de Navarra (Spain); Ministry of Science and Innovation, Institute of Health Carlos III, co-funded by the European Fund for Economic and Regional Development (FEDER) [PI18/01195], Ministry of Science and Innovation, Institute of Health Carlos III [CB16/11/00371 and CB16/11/00483] and VIRTO group.